City Therapeutics, Inc. Common Stock Total Assets

Latest as of June 2026: $208.61 Million USD

City Therapeutics, Inc. Common Stock total assets. Based on the latest financial reports, City Therapeutics, Inc. Common Stock (CTY) holds total assets worth $208.61 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see City Therapeutics, Inc. Common Stock (CTY) market capitalisation for the company's overall valuation and market capitalisation.

Total Assets of City Therapeutics, Inc. Common Stock (2005–2025)

Total assets of City Therapeutics, Inc. Common Stock from 2005 to 2025. This chart illustrates how City Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See CTY share price today for real-time trading data and today's change.

City Therapeutics, Inc. Common Stock - Asset Composition Analysis

City Therapeutics, Inc. Common Stock Total Assets Breakdown (December 2025)

City Therapeutics, Inc. Common Stock total assets breakdown as of December 2025. City Therapeutics, Inc. Common Stock's total assets of $208.61 Million consist of 78.0% current assets and 22.0% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 75.3%
Accounts Receivable $1.21 Million 0.8%
Inventory $0.00 0.0%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $0.00 0.0%
Goodwill $0.00 0.0%

Asset Composition Trend (2005–2025)

This chart illustrates how City Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore City Therapeutics, Inc. Common Stock current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: City Therapeutics, Inc. Common Stock's current assets represent 78.0% of total assets in 2025, an increase from 0.0% in 2005.
  • Cash Position: Cash and equivalents constituted 75.3% of total assets in 2025, up from 0.0% in 2005.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
  • Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.

City Therapeutics, Inc. Common Stock Competitors by Total Assets

Key competitors of City Therapeutics, Inc. Common Stock based on total assets are shown below.

Company Country Total Assets
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
USA $11.57 Billion
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
USA $1.26 Billion
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
China CN¥13.56 Billion
Metsera, Inc. Common Stock
NASDAQ:MTSR
USA $639.66 Million
Xiamen Amoytop Biotech Co Ltd
SHG:688278
China CN¥3.21 Billion
SOLENO THERAPEUT. DL-001
F:6XC
Germany €563.83 Million
89bio Inc
NASDAQ:ETNB
USA $603.49 Million
LegoChem Biosciences Inc
KQ:141080
Korea ₩652.93 Billion

City Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.71 0.73 0.80
Quick Ratio 2.71 0.73 0.80
Cash Ratio 0.00 0.00 0.00
Working Capital $110.93 Million $-923.00 Million $-505.00 Million

City Therapeutics, Inc. Common Stock - Advanced Valuation Insights

This section examines the relationship between City Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio -
Latest Market Cap to Assets Ratio 6.08
Asset Growth Rate (YoY) 3.0%
Total Assets $149.77 Million
Market Capitalization $911.01 Million USD

Valuation Analysis

Premium Asset Valuation: The market values City Therapeutics, Inc. Common Stock's assets at a significant premium (6.08x), suggesting investors see substantial growth potential or unique competitive advantages.

Positive Asset Growth: City Therapeutics, Inc. Common Stock's assets grew by 3.0% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for City Therapeutics, Inc. Common Stock (2005–2025)

The table below shows the annual total assets of City Therapeutics, Inc. Common Stock from 2005 to 2025.

Year Total Assets Change
2025-12-31 $149.77 Million +3.04%
2024-12-31 $145.35 Million -99.31%
2019-12-31 $21.00 Billion +2.02%
2018-12-31 $20.58 Billion -1.37%
2017-12-31 $20.87 Billion -1.32%
2016-12-31 $21.15 Billion -1.50%
2015-12-31 $21.47 Billion -4.40%
2014-12-31 $22.46 Billion +40.27%
2013-12-31 $16.01 Billion -4.21%
2012-12-31 $16.71 Billion -3.89%
2011-12-31 $17.39 Billion +7768.78%
2010-12-31 $221.00 Million -81.03%
2009-12-31 $1.17 Billion +279.48%
2008-12-31 $307.00 Million -56.14%
2007-12-31 $700.00 Million -95.29%
2006-12-31 $14.85 Billion -1880.58%
2005-12-31 $-834.00 Million --

About City Therapeutics, Inc. Common Stock

NASDAQ:CTY USA Biotechnology
Market Cap
$911.01 Million
Market Cap Rank
#9050 Global
#2589 in USA
Share Price
$18.10
Change (1 day)
-4.64%
52-Week Range
$16.41 - $22.14
All Time High
$22.14
About

City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as re… Read more